Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
A Precision Knock-In Strategy for Rabbit Pharming
2026-11-20
A 2025 study reports that targeting a recombinant reporter gene to the rabbit CSN2 milk-protein locus produced 15–20 g/L in milk from homozygous animals. The finding supports a strong locus-specific expression effect, while the small reporter-focused dataset leaves questions about protein-specific performance, total production, product quality and regulatory translation.
CSN2 Targeting and Rabbit Milk Pharming
2026-11-20
A 2025 study linked targeted insertion at the rabbit CSN2 locus with unusually high milk concentrations of a tdTomato reporter. The findings support a promising expression strategy, but the evidence remains limited to a small number of animals, a reporter protein, and comparisons with historical rather than matched controls.
What Deuterium-Labeled Degarelix Demonstrates
2026-11-19
Huang and colleagues developed a mass-distinct, deuterium-labeled form of degarelix acetate for analytical use as an internal standard. The study’s main contribution was a selective labeling strategy and structural characterization—not evidence about acetoacetate biology, therapeutic performance, or clinical outcomes.
A CSN2-Driven Strategy for Rabbit Pharming
2026-11-19
A literature-focused analysis of a 2025 study that used locus-targeted insertion at the rabbit CSN2 locus to test whether an endogenous milk-protein regulatory environment could raise recombinant protein output. The evidence is promising but remains a reporter-based, concentration-centered proof of concept rather than a demonstration of therapeutic-product performance.
How Claustrum Gene Maps Gain Meaning
2026-11-18
Comparative claustrum mapping shows how gene expression, topology and detection chemistry can support structural comparisons without proving equivalent function. The article explains the role of Cyanine 3 Tyramide as a fluorescent dye for biomedical research and examines what the reported mammalian data establish—and what remains uncertain.
What the Deuterium-Labeled Degarelix Study Shows
2026-11-18
A literature-focused analysis of a synthesis study that created deuterium-labeled degarelix as a mass-distinct analytical internal standard, clarifying what its isotope data establish—and what they do not establish about acetoacetate or metabolic disease.
Deuterium-Labeled Degarelix as an Analytical Standard
2026-11-17
A paper-centred interpretation of a synthetic chemistry study that uses deuterium incorporation in a naphthalene-containing amino-acid unit to generate a mass-distinct degarelix reference material.
What Deuterated Degarelix Synthesis Establishes
2026-11-17
The cited study addressed a measurement problem: how to produce a deuterium-labeled degarelix acetate suitable for use as a mass-spectrometric internal standard. Its reported 14% overall yield, isotopologue analysis, and high-resolution mass confirmation support the synthetic and analytical assignment of the labeled peptide, but do not establish clinical efficacy, metabolic activity, or any performance claim for acetoacetate materials.
Why a CSN2 Rabbit Line Raised Pharming Yields
2026-11-16
This editorial examines how targeted placement of a reporter under the endogenous CSN2 promoter was linked to high milk concentrations in a rabbit line, and why that result is promising but not yet a general benchmark for therapeutic production. It separates locus-level mechanism, inheritance and concentration measurements from the study’s small sample and cross-study comparisons.
Acetoacetate Evidence: Mechanism, Measurement, Limits
2026-11-16
A deuterium-labeling study of degarelix provides a useful framework for interpreting isotope-resolved mass spectrometry, but it does not establish biological activity, metabolic effects, or clinical relevance for acetoacetic acid sodium salt.
When Research Context Changes a Result
2026-11-15
A measured result acquires meaning from the question, model, material identity, and readout used to obtain it. Comparing acetoacetate-related metabolic interpretation with a deuterium-labeling study of degarelix shows why analytical success, chemical yield, and biological relevance must not be treated as interchangeable evidence.
Interpreting High-Yield Rabbit Pharming Evidence
2026-11-14
A critical assessment of a targeted rabbit line, its reported milk-protein yield, historical comparisons, and the evidence still needed to establish reproducibility and broader applicability.
What a CSN2-Targeted Rabbit Line Shows
2026-11-13
A 2025 study tested whether placing a reporter transgene at the rabbit CSN2 locus could use the native β-casein regulatory environment to increase protein accumulation in milk. The reported 15–20 g/L output in two homozygous females is striking, but the result concerns a fluorescent reporter and does not by itself establish therapeutic protein activity, manufacturing consistency, or regulatory readiness.
What High-Yield Rabbit Pharming Evidence Shows
2026-11-13
A 2025 rabbit study reported 15–20 g/L tdTomato in milk from two homozygous animals using a CSN2-locus knock-in. The result is striking but does not yet establish general therapeutic-protein manufacturing performance.
Deuterium-Labeled Degarelix: Chemistry Evidence
2026-11-12
A paper-centred interpretation of a synthetic-chemistry study that used hydrogen–deuterium exchange to create a mass-distinct degarelix intermediate and characterized the labeled product by chromatographic, mass-spectrometric and nuclear-magnetic-resonance methods. The evidence supports chemical feasibility and analytical characterization, while biological performance remains outside the study design.